newsfilter
← Latest News
GlobeNewswire·

SAB BIO to Participate in Upcoming Investor Conferences

MIAMI, Nov. 09, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and